STREAM Trial Reveals Risks of Statin Discontinuation in Seniors

A recent study indicates that older adults without cardiovascular disease may safely stop statin therapy, but risks remain.

A
Aapla Nagpur Desk
19 Nov 2026, 10:29 AM IST · 2 min read
Source: Medscape
STREAM Trial Reveals Risks of Statin Discontinuation in Seniors
KEY TAKEAWAYS
1

The STREAM trial suggests stopping statins is noninferior to continuing for older adults without CV disease.

2

About 1 in 40 participants who discontinued statins experienced avoidable events.

3

Quality of life did not improve significantly for those who stopped taking statins.

A recent study presented at the American Heart Association's Scientific Sessions 2026 has provided new insights into the safety of statin discontinuation among older adults without cardiovascular disease. The STREAM trial, which involved 1,880 participants aged 70 and above, found that stopping statin therapy was noninferior to continuing treatment in terms of reducing cardiovascular death and related risks. However, the data also indicated that major cardiovascular events were more frequent among those who stopped taking the medication.

The trial, led by Dr. Nicolas Rodondi from the University of Bern, aimed to address the growing concern among older patients regarding the necessity of long-term statin use for primary prevention. While the findings suggest that discontinuing statins may be a viable option, experts like Dr. Amit Khera from UT Southwestern Medical Center caution that the decision should be carefully considered. Khera noted that approximately 1 in 40 participants who stopped their statin therapy experienced events that could have been prevented had they continued treatment.

The study's primary endpoint evaluated nonfatal myocardial infarction, nonfatal ischemic stroke, and all-cause mortality over two years. The results showed a minimal difference in event-free survival time between the two groups, confirming noninferiority. However, the long-term implications were concerning, as event rates increased more significantly in the discontinuation group over a four-year follow-up period.

Quality of life assessments revealed no significant improvements for participants who stopped taking statins. Measures of physical strength and pain levels did not show meaningful differences between the two groups. Dr. Karen Alexander from Duke University emphasized that while the trial offers valuable data, it does not provide a definitive answer on whether older adults should discontinue statins. She highlighted the importance of individualized decision-making based on patient circumstances and preferences.

As the medical community continues to evaluate the implications of these findings, patients are encouraged to engage in discussions with their healthcare providers regarding the risks and benefits of statin therapy. The STREAM trial underscores the need for personalized approaches to treatment decisions, particularly for older adults with multiple health considerations. The trial was funded by the Swiss National Science Foundation, and the researchers reported no conflicts of interest.

💬What did you think of this story?What did you think?

Read Next